bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
2024年8月24日 - 6:15AM
ビジネスワイヤ(英語)
Edwards held CFO position at bioAffinity for
nine years, leading Company through successful IPO
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company focused on the need for
noninvasive tests for the detection of early-stage cancer, today
announced that Michael Dougherty has resigned as Chief Financial
Officer to accept a CFO position in the Pacific Northwest in the
energy industry.
J. Michael Edwards, who served as bioAffinity’s consulting CFO
from 2014 to 2023 and oversaw the Company’s initial public offering
in 2022, will serve as interim CFO until a permanent CFO is
appointed. Dougherty will continue to serve in the role of CFO
until Sept. 15, 2024, and will assist in the transition.
“We expect a seamless transition given the strong team and
financial processes that Mike Dougherty has put in place and
Michael Edwards’ extensive experience as bioAffinity’s previous
CFO,” bioAffinity Technologies President and CEO Maria Zannes said.
“During his tenure, Mike Dougherty played an important role in the
acquisition of Precision Pathology Laboratory Services and the
growth in adoption of CyPath® Lung, our noninvasive test for lung
cancer. Mike has made significant contributions to bioAffinity’s
success and is leaving us in good hands. We wish him the very best
in his future endeavors.”
“I am grateful for the opportunity to work for bioAffinity
Technologies and support its mission for the early detection of
lung cancer. I’m proud of our accomplishments and leave with mixed
emotions for this unexpected opportunity in the Pacific Northwest
closer to home and family,” Dougherty said. “I have every
confidence in the team we built and the financial planning and
processes we implemented. I know this team will ensure the ongoing
success of the Finance Department.”
Edwards has more than 25 years of experience in corporate
finance and accounting. Previously, he served as CFO of
CytoBioscience, Inc. and OncoVista Innovative Therapies, Inc. He is
a certified public accountant and holds an MBA from The University
of Texas McCombs School of Business.
bioAffinity Technologies will initiate a search for a permanent
CFO immediately.
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and
artificial intelligence (AI) to identify cell populations in
patient sputum that indicate malignancy. Automated data analysis
helps determine if cancer is present or if the patient is
cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that
is preferentially taken up by cancer and cancer-related cells.
Clinical study results demonstrated that CyPath® Lung had 92%
sensitivity, 87% specificity and 88% accuracy in detecting lung
cancer in patients at high risk for the disease who had small lung
nodules less than 20 millimeters. Diagnosing and treating
early-stage lung cancer can improve outcomes and increase patient
survival. For more information, visit www.cypathlung.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and other diseases of
the lung and broad-spectrum cancer treatments. The Company’s first
product, CyPath® Lung, is a noninvasive test that has shown high
sensitivity, specificity and accuracy for the detection of
early-stage lung cancer. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Laboratory Services, a
subsidiary of bioAffinity Technologies. For more information, visit
www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding a seamless transition given the strong
financial team and processes, the ongoing success of the Finance
Department and Edwards’ expected contributions to the Company.
These forward-looking statements are subject to various risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the ability to successfully transition from
one CFO to another and the other factors discussed in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023,
and its subsequent filings with the SEC, including subsequent
periodic reports on Forms 10-Q and 8-K. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. While the Company believes these forward-looking
statements are reasonable, readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. The information in this release is provided only as of
the date of this release, and the Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240823810079/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498 BIAF@redchip.com
bioAffinity Technologies (NASDAQ:BIAF)
過去 株価チャート
から 8 2024 まで 9 2024
bioAffinity Technologies (NASDAQ:BIAF)
過去 株価チャート
から 9 2023 まで 9 2024